The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125653661 12565366 1 I 20141218 20160718 20160718 EXP US-CELGENEUS-USA-2014124895 CELGENE NAHLEH Z. SWOG S0800 (NCI CDR0000636131): ADDITION OF BEVACIZUMAB TO NEOADJUVANT NAB-PACLITAXEL WITH DOSE-DENSE DOXORUBICIN AND CYCLOPHOSPHAMIDE IMPROVES PATHOLOGIC COMPLETE RESPONSE (PCR) RATES IN INFLAMMATORY OR LOCALLY ADVANCED BREAST CANCER.. BREAST CANCER RES TREAT. 2016 JUL 08;. 0.00 Y 0.00000 20160718 OT US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125653661 12565366 1 PS ABRAXANE PACLITAXEL 1 Intravenous drip U UNKNOWN 21660 100 MG/M**2 INJECTION FOR INFUSION /wk
125653661 12565366 2 SS ABRAXANE PACLITAXEL 1 Intravenous drip U UNKNOWN 21660 125 MG/M**2 INJECTION FOR INFUSION /wk
125653661 12565366 3 SS Doxorubicin DOXORUBICIN 1 Intravenous drip U 21660 60 MG/M**2 INJECTION QOW
125653661 12565366 4 SS Doxorubicin DOXORUBICIN 1 U 21660
125653661 12565366 5 SS CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE 1 Intravenous drip U 21660 600 MG/M**2 INJECTION QOW
125653661 12565366 6 SS CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE 1 U 21660
125653661 12565366 7 SS Pegfilgrastim PEGFILGRASTIM 1 Subcutaneous U 21660 6 MG INJECTION QOW
125653661 12565366 8 SS Pegfilgrastim PEGFILGRASTIM 1 U 21660
125653661 12565366 9 SS Bevacizumab BEVACIZUMAB 1 Intravenous drip U 21660 10 MG/KG INJECTION QOW
125653661 12565366 10 SS Bevacizumab BEVACIZUMAB 1 U 21660

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125653661 12565366 1 Breast cancer
125653661 12565366 2 Inflammatory carcinoma of the breast
125653661 12565366 3 Breast cancer
125653661 12565366 4 Inflammatory carcinoma of the breast
125653661 12565366 5 Breast cancer
125653661 12565366 6 Inflammatory carcinoma of the breast
125653661 12565366 7 Breast cancer
125653661 12565366 8 Inflammatory carcinoma of the breast
125653661 12565366 9 Breast cancer
125653661 12565366 10 Inflammatory carcinoma of the breast

Outcome of event

Event ID CASEID OUTC COD
125653661 12565366 DE
125653661 12565366 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
125653661 12565366 Acute respiratory distress syndrome
125653661 12565366 Anaemia
125653661 12565366 Blood disorder
125653661 12565366 Breast cancer
125653661 12565366 Cardiac failure
125653661 12565366 Death
125653661 12565366 Deep vein thrombosis
125653661 12565366 Diarrhoea
125653661 12565366 Dyspnoea
125653661 12565366 Embolism
125653661 12565366 Enterocolitis infectious
125653661 12565366 Febrile neutropenia
125653661 12565366 Hypercalcaemia
125653661 12565366 Hypertension
125653661 12565366 Nausea
125653661 12565366 Pain
125653661 12565366 Palmar-plantar erythrodysaesthesia syndrome
125653661 12565366 Pulmonary embolism
125653661 12565366 Respiratory failure
125653661 12565366 Sepsis
125653661 12565366 Thrombocytopenia

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

no results found